In a cost-effectiveness analysis comparing traditional bariatric surgery and GLP-1 agonist use for obesity management, the monthly cost based on 2023 pricing for both non-compounded SMA and liraglutide was approximately $1600 monthly [21]. This evidence concerns the gene GCG and obesity disorder.